Leukemia Therapeutics Market – Regional Insights
Leukemia cases are projected to be more in the developed economies such as North America and Europe, owing to genetic mutations caused by radiation exposure. According to Center for Disease Control and Prevention (CDC), in the U.S. around 45,360 people were diagnosed with leukemia in 2013, leading to 23,549 fatalities (13,625 men and 9,924 women). The condition is more prevalent among men than women. Leukemia makes up about 3% of all new cancer cases. Also according to the World Cancer Research Fund, one third of the cancer cases occur in economically developed economies such as US and Europe, owing to lack of physical activity, obesity, and/or poor nutrition. Furthermore, around 90% of the leukemia occur in the middle age and develop with the aging.
Furthermore, in emerging economies of Asia Pacific such as China and India, the leukemia therapeutics market is expected to grow at significant rate due high unmet medical needs. Rising strategic partnership and acquisition by the market players is expected to bolster the market growth. For instance, in April 2019, Astellas Pharma Inc. a japan based company and Concerto HealthAI, a real-world data (RWD), artificial intelligence (AI) technology and outcomes science company collaboratively launched Real-World Evidence (RWE) initiative on Acute Myeloid Leukemia in order to improve treatment of patients with suffering from FLT3 mutation-positive relapsed AML.
Leukemia Therapeutics Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients